| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/10-1/50 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | TASK; Task-1; cTBAK-1 |
| Entrez GeneID | 16527; |
| WB Predicted band size | 45kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse |
| Immunogen | Synthetic peptide corresponding to residues near the C terminal of human potassium channel, subfamily K, member 3 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇关于KCNK3抗体的代表性文献示例(仅供参考，具体文献请核实数据库)：
---
1. **文献名称**: *"KCNK3 channel contributes to hypoxia-induced pulmonary hypertension"*
**作者**: Antigny F, et al.
**摘要**: 研究使用KCNK3特异性抗体发现，缺氧条件下肺动脉平滑肌细胞中KCNK3蛋白表达下调，其功能抑制导致肺动脉收缩异常，与肺动脉高压发病相关。
2. **文献名称**: *"Autoantibodies targeting KCNK3 in idiopathic pulmonary arterial hypertension"*
**作者**: Lambert M, et al.
**摘要**: 通过免疫沉淀和抗体阻断实验，发现特发性肺动脉高压患者血清中存在KCNK3自身抗体，这些抗体通过抑制通道活性促进血管重塑。
3. **文献名称**: *"Pharmacological modulation of TASK-1 (KCNK3) channels as a therapeutic strategy"*
**作者**: Ma L, et al.
**摘要**: 利用KCNK3抗体验证小分子化合物对通道蛋白的靶向作用，证明抗体在评估药物效价及蛋白构象变化中的关键作用。
---
**注**：若需具体文献，建议在PubMed或Web of Science中以关键词“KCNK3 antibody”或“TASK-1 antibody”检索近年研究。
The KCNK3 antibody is associated with the study of potassium channel subfamily K member 3 (KCNK3), also known as TASK-1 (TWIK-related acid-sensitive K+ channel). This protein, encoded by the *KCNK3* gene, forms a pH- and oxygen-sensitive voltage-independent potassium channel involved in maintaining resting membrane potential and cellular excitability. It is expressed in various tissues, including the heart, lungs, and nervous system. Dysregulation of KCNK3 has been implicated in pathologies such as pulmonary arterial hypertension (PAH), atrial fibrillation, and cancer.
In research, KCNK3 antibodies are primarily used to detect and quantify the protein in experimental models, aiding in understanding its physiological roles and disease mechanisms. Notably, autoantibodies targeting KCNK3 have been identified in some PAH patients, contributing to channel dysfunction by reducing potassium currents and promoting vasoconstriction and vascular remodeling. These findings highlight KCNK3 as a potential therapeutic target, with studies exploring agents like treprostinil to restore channel activity.
Current investigations focus on elucidating KCNK3's structural biology, regulatory pathways, and interactions with other ion channels or signaling molecules. Challenges include clarifying its tissue-specific roles and developing selective modulators. The development of high-affinity, specific KCNK3 antibodies remains critical for advancing both basic research and clinical diagnostics in channelopathy-related diseases.
×
